Melanotan 2 Spec.
Alias:Melanotan 2, Melanotan, Mt II, Melanotan 2 (MT2)Melanotan-II
Purity (by HPLC): 99.00%
Molecular Formula: C50H69N15O9
Molecular weight: 1024.2
Packing:Discreet and Disguised packing to pass the customs.
Storage Condition; away from light, cold storage (2-8 degree)
Usage:Keeping Health and Promoting Growth. prevention sunlight-induce skin cancer; Sexual Dysfunction & Fat Decomposition.
Promoting skin tanning. protecting against the harmful effects of ultraviolet radiation from sunlight.
How to use Melanotan 2
Mixing the solution
Flip off the cap from the Melanotan 2 Tanning Injection vial.
Wipe the surface of the top of the vial with the enclosed alcohol wipe and discard the wipe.
Wipe the surface of the injectable water tube (or glass water vial depending on the pack ordered) with the enclosed alcohol wipe and discard the wipe.
Remove the enclosed syringe from the packaging. Making sure the injectable water tube is upright, insert the needle of the syringe into the sidewall of the water.
Now pull back the plunger of the syringe so you withdraw 1ml of water and slowly pull the syringe out.
Insert the syringe into the Melanotan 2 Tanning Injection vial and depress the plunger so you completely empty the syringe of the water and slowly remove the syringe from the vial. Do not shake the solution.
Place the Melanotan 2 solution in the fridge for storage until ready for use.
Make sure you put the syringe caps on and carefully dispose of it.
You have now mixed your Melanotan 2 Tanning Injection solution. Please store the solution in the fridge.
How to use Melanotan II for tanning
Melanotan II is typically provided in vials containing 10 mg of lyophilized (freeze-dried) powder. The vials are reconstituted with a convenient amount of bacteriostatic or sterile water, added to the vial by syringe. An example convenient amount of water is 2.5 mL. When this amount of water is used, the resulting solution contains 4 mg of MT-II per mL. If for example wishing to take a dose of 1 mg, a volume of 0.25 mL, or "25 IU" as marked on an insulin syringe, would be taken by injection. Injection may be subcutaneous, intramuscular, or intravenous, according to personal preference.
Injection typically is only once per day, but where a person is first trying the drug and judging tolerance, injection may be divided into two smaller amounts per day.
Typical dosage range is 0.5 to 2.0 mg/day, with a preferred range of 0.5 to 1.0 mg/day. However, it's best to first assess tolerance with lower dosing of 0.25 mg at a time.
After reconstitution, a Melanotan II vial should preferably be consumed entirely within 30 days. Prior to reconstitution, MT-II should be stored in the refrigerator or freezer, but it's acceptable for it to be shipped without refrigeration.
Use generally should be discontinued if MT-II, in the individual case, causes problems with increased growth, number, or darkness of moles.
Melanotan II's effect is fairly long-lasting. It can even be the case that it takes a year or more for a cycle's effect to largely disappear. Use of maintenance cycles can maintain effect indefinitely. As a rule of thumb, maintenance typically requires about 2 to 3 times as much MT-II per year as was needed for the first cycle. This can be taken either as a total of 2 to 3 cycles per year done in the same way as the initial cycle, or any more frequent dosing pattern providing this total amount of MT-II per year.
Melanotan II (PT-14) is a synthetic analogue of the peptide hormone α-melanocyte-stimulating hormone (α-MSH).
Melanotan II acts as a non-selective agonist of the melanocortin receptors, MC1, MC3, MC4, MC5.
The melanogenesis produced by melanotan II is caused by activation of the MC1 receptor, whereas its sexual effects are thought to be related to its ability to activate the MC4 receptor (though the MC3 is thought to possibly also be involved).
Other effects of melanotan II, mostly regarded as adverse effects, include flushing, nausea, vomiting, stretching, yawning, and loss of appetite (the last via activation of MC4).
Melanotan II (MT-2) Description
Melanotan II is a synthetic peptide variant of a peptide hormone, called alpha-Melanocyte stimulating hormone or MSH that is naturally produced in the body and is responsible for stimulating melanogenesis, a peptide process for pigmentation of the skin. Alpha-MSH activates certain melanocortin receptors in the process of exerting its effects. Indeed, MSH also exerts potent influence over lipid metabolism, appetite, and sexual libido via these melanocortin receptors. As a result, Melanotan-1 sunless skin tanning effects. While Melanotan 2 and PT-141 have been studied at length as a potential remedies for the treatment of sexual dysfunction, Melanotan-1 has been researched extensively for use in protecting against the harmful effects of ultraviolet radiation from sunlight due to its melanogenesis-stimulating properties.
Melanotan 2 Tanning Injections (otherwise known as MT2) was first synthesized at the University of Arizona. Researches there knew that onc of the best defenses against skin cancer was melanin activated in the skin, a tan. They hypothesized that an effective way to reduce skin cancer rates in people would be to induce the body's natural pigmentary system to produce a protective tan prior to UV exposure. The body's naturally occuring hormone MSH causes melanogenesis, a process by which the skin's pigment cells (melanocytes) produce the skin's pigment (melanin). They tested to see if administering this endogenous hormone to the body directly could be an effective method to cause sunless tanning. What they found was that while it appeared to work, natural MSH had too short a half life in the body to be practical as a therapeutic drug. So they decided to find a more potent and stable alternative, one that would be more practical.
After synthesizing and screening hundreds of molecules, the researchers headed by Victor J. Hruby and Mac E. Hadley, found a peptide, [Nle4, D-Phe7] MSH, that was approimately 1,000 times more potent than the natural MSH. They dubbed this new peptide molecule, "Melanotan" (later Melanotan-1, now know as afamelanotide). They subsequently developed another analog, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2), which they called "Melanotan" Tanning Injections. The scientists hoped to use these peptides to combat melanoma by stimulating the body's natural pigmentary mechanism to create a tan without first needing exposure to harmful levels of UV radiation. This in turn, they hypothesized, could reduce the potential for skin damage that can eventually lead to skin cancer.
A pilot phase I clinical trial conducted on three males by the College of Medacine, Pharmacology Department, University of Arizona in Tuscon, Arizona pulished in 1996 reported that, "Melanotan" Tanning Injections has tanning activity in humans given only 5 low doses every other day by subcutaneous injection." The side effects reported were mild nausea and a "stretching and yawning complex" that correlated with spontaneous penile erections.
The Department of Pharmacology, University of Arizona College of Medacin published in 1998 that involved 10 men who suffered from psychogenic erectile dysfunction. Their trial concluded that, "Melanotan" Tanning Injections is a potent initiator of erections in men with pyschogenic erectile dydfunction and has manageable side effects at a dose of 0.025mg/kg.
Melanotan II Tanning Injections is a potent initiator of penile erection in men with ecrectile dysfunction.